Columbus OH 三阴性乳腺癌临床试验
16项针对 三阴性乳腺癌的研究正在 Columbus及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
招募中1 期
- Ohio State University Comprehensive Cancer Center, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
招募中观察性研究
- The Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
招募中1/2 期
- Local Institution - 0102, Columbus
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
招募中1/2 期
- Ohio State University, Columbus
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- Ohio State University CRS, Columbus
- Ohio Health Research Institute, Columbus
- Anita Stewart Oncology Center, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
招募中1 期
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
招募中1/2 期
- The Ohio State University, Columbus
SMP-3124LP in Adults With Advanced Solid Tumors
招募中1/2 期
- Ohio State University, Columbus
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
招募中
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of LY4175408 in Participants With Advanced Cancer
招募中1 期
- The Ohio State University (OSU) Wexner Medical Center, Columbus
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
招募中2 期
- The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
招募中2 期
- Ohio State University Medical Center, Columbus
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
招募中
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
招募中1/2 期
- The Ohio State University, Columbus
其他城市的 三阴性乳腺癌试验
- Houston, TX42 项研究
- New York City, NY31 项研究
- Nashville, TN28 项研究
- Los Angeles, CA27 项研究
- Boston, MA26 项研究
- San Antonio, TX23 项研究
- St. Louis, MO21 项研究
- Arlington, VA20 项研究
- Atlanta, GA20 项研究
- Dallas, TX18 项研究
- Chicago, IL16 项研究
- Grand Rapids, MI15 项研究
Columbus的其他研究
- 非小细胞肺癌57 项研究
- 乳腺癌40 项研究
- 卵巢癌39 项研究
- 癌症（所有类型）38 项研究
- 肺癌37 项研究
- 急性髓系白血病35 项研究
- 慢性淋巴细胞白血病28 项研究
- 转移性癌症27 项研究
- 子宫内膜癌25 项研究
- 前列腺癌24 项研究
- 多发性骨髓瘤24 项研究
- 结直肠癌24 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。